News
ABUS
3.655
-0.41%
-0.015
Weekly Report: what happened at ABUS last week (1026-1030)?
Weekly Report · 11/02 10:08
Healthcare stocks with strong revenue growth and attractive valuations
Seeking Alpha · 10/27 11:10
Weekly Report: what happened at ABUS last week (1019-1023)?
Weekly Report · 10/26 10:08
FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B Study
Benzinga · 10/22 14:25
Arbutus Biopharma's AB-101 Gets FDA Hold Lifted In Hepatitis B Program
NASDAQ · 10/22 14:12
FDA lifts clinical hold on Arbutus Biopharma AB-101 IND application
TipRanks · 10/22 11:40
Arbutus Biopharma Says FDA Lifts Clinical Hold On AB-101 IND, Company May Now Engage In Additional Clinical Development For AB-101 In US
Benzinga · 10/22 11:35
Weekly Report: what happened at ABUS last week (1012-1016)?
Weekly Report · 10/19 10:08
Weekly Report: what happened at ABUS last week (1005-1009)?
Weekly Report · 10/12 10:13
Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure
Seeking Alpha · 10/08 17:01
Largest borrow rate increases among liquid names
TipRanks · 10/08 12:45
Weekly Report: what happened at ABUS last week (0928-1002)?
Weekly Report · 10/05 10:12
Largest borrow rate increases among liquid names
TipRanks · 10/02 12:45
Arbutus gains on plans to buy back 46M shares in tender offer
Seeking Alpha · 09/30 16:51
Arbutus Biopharma’s US$230 Million Share Buyback Oversubscribed
TipRanks · 09/30 12:09
Press Release: Arbutus Announces Preliminary Results of Its US$230 Million Modified "Dutch Auction" Tender Offer
Dow Jones · 09/30 11:30
Weekly Report: what happened at ABUS last week (0921-0925)?
Weekly Report · 09/28 10:08
After Hours Most Active for Sep 25, 2026 : FTXN, ABUS, FTXH, CMCSA, NVDA, CSCO, JPM, BMNR, EQT, CNP, PFE, CVS
NASDAQ · 09/25 20:24
After Hours Most Active for Sep 22, 2026 : RIG, NIO, INTC, NVDA, QQQ, CSCO, CDE, ABUS, BMY, NU, AAPL, BAC
NASDAQ · 09/22 20:24
Noteworthy Tuesday Option Activity: ALAB, ABUS, POR
NASDAQ · 09/22 19:22
More
Webull provides a variety of real-time ABUS stock news. You can receive the latest news about Arbutus Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.